Quick Answer
Dyne Therapeutics, Inc. reported Shares Outstanding of 164.95 million shares for fiscal year 2025.
Dyne Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 164.95M | +61.2% |
| 2024 | 102.32M | +66.5% |
| 2023 | 61.47M | +10.5% |
| 2022 | 55.64M | +7.9% |
| 2021 | 51.57M | +14.4% |
| 2020 | 45.08M | +1642.7% |
| 2019 | 2.59M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 142.61M | +40.2% | +24.7% |
| June 30, 2025 | 114.34M | +14.2% | +0.6% |
| March 31, 2025 | 113.63M | +30.5% | +11.1% |
| December 31, 2024 | 102.32M | +66.5% | +0.6% |
| September 30, 2024 | 101.75M | +65.9% | +1.6% |
| June 30, 2024 | 100.12M | +64.1% | +15.0% |
| March 31, 2024 | 87.09M | +49.4% | +41.7% |
| December 31, 2023 | 61.47M | +10.5% | +0.2% |
- Dyne Therapeutics, Inc. showed an increase of +61.2% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Dyne Therapeutics, Inc.’s shares outstanding has grown by 6277.3% (from 2.59 million shares to 164.95 million shares).
- The most recent figure is from Dyne Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: